NICE guideline on acute coronary syndromes
A brief summary of NICE’s clinical guideline on the management of acute coronary syndromes, which covers rehabilitation and aims to improve survival and quality of life
AWMSG Advice on oral anticoagulation for non-valvular atrial fibrillation
Recommendations for primary care on the role of oral anticoagulant treatment in people with non-valvular atrial fibrillation.
BSR giant cell arteritis guideline
This summary outlines the general principles of identifying and treating patients with giant cell arteritis in primary care and specialist settings. It is recommended that general practitioners refer patients with suspected giant cell arteritis to a clinician with appropriate specialist expertise.
NICE stable angina guideline
A brief summary of NICE's clinical guideline on the management of stable angina. Includes care pathway algorithm, counselling, and secondary prevention.
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Educational resources
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.
PP-XAR-GB-1856 November 2020
Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines for Pharmacy. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
PP-XAR-GB-1857 November 2020
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
PP-XAR-GB-1858 November 2020
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Stable peripheral arterial disease guideline
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.